Ability Pharma has a first-in-class autophagy driven treatment for metastatic pancreatic cancer, one of the deadliest cancers, and its interim blinded Phase 2b data suggested a significant improvement over the current standard of care.
Aeovian is a clinical-stage biotherapeutics company developing mTORC1-specific inhibitors.
DalCor was created based on a Phase 3-ready precision cardiology asset from the Montreal Heart Institute, a leader in cardiology research.
enGene’s lead program has competitive efficacy and safety data and a distinct delivery advantage, positioning it as the go-to treatment of choice for urologists.
Epitopea had a novel approach to identify tumor specific antigens that are highly immunogenic and shared across patients to enable true off-the-shelf cancer vaccines.
Find Therapeutics' platform that could design differentiated peptide-based therapies for intramembrane targets and its lead asset showed promising pre-clinical data.
Glycomine has a substrate replacement therapy that directly bypass the mutated enzyme in patients with PMM2-CDG; it is not only a first-in-class treatment but also the only disease modifying treatment.
Kainova’s unique platform produced potential best-in-class assets against valuable GPCR targets, its lead assets demonstrated best-in-class data in the pre-clinical setting.
Oligon is a pre-clinical biotech company developing the SeekR™ platform to enable self-delivering siRNA therapies beyond the liver.
Phenomic AI’s platform integrates one of the world's largest single-cell RNA (scRNA) datasets from human tissues, enabling the analysis of complex cell-cell interactions within multi-cell systems.
Profound’s MRI guided ablation not only improves survival outcome but is also significantly less invasive compared to traditional approach.
Thryv has a first-in-class treatment for a rare pediatric cardiology disease called Long QT Syndrome that demonstrated strong efficacy signal in its Phase 2a study.
